6th isirv-AVG Conference
Advances in Respiratory Virus Therapeutics

Tuesday 13th - Thursday 15th November 2018
Hilton Washington DC/ Rockville Hotel, Washington DC, USA

Preliminary Programme

Tuesday 13 November	
08:30-08:45	**Welcome & Opening**
08:45-09:30	**Session 1:** Keynote Lecture: BARDA perspectives on advancing respiratory virus therapeutics
09:30-11:00	**Session 2 :** Symposium - Preclinical Topics • Eritoran, a TLR 4 antagonist *Stefanie Vogel, University of Maryland, Baltimore, MD, USA* • Matrix Metalloproteinases *Kevin Harrod, University of Alabama, Birmingham, AL, USA* • HA Mini-Binders Proof of Concept in Mice and Non-Human Primates *Deborah Fuller, University of Washington, Seattle, WA, USA*
11:00-11:30	**Coffee Break**
11:30-13:00	**Session 3:** Oral abstract session 1- Preclinical Papers
13:00-14:00	**Lunch**
14:00-15:00	**Session 4:** Symposium- Clinical Trial Design Issues • Clinical pharmacology considerations for Influenza and RSV trials *FDA Speaker* • Considerations of use of PROs in SARI and hospitalized influenza studies *FDA COA Speaker*
15:00-15:30	**Coffee Break**
15:30-17:00	**Session 5:** Oral Abstracts Session 2- Preclinical and Phase 1 Clinical Papers
17:00-18:00	Poster session 1

Wednesday 14 November	
08:30-10:35	**Session 6:** Symposium - Updates on Clinical Trials Evaluation of Anti-HA Stem Monoclonal Antibody FluA in Two Phase 2 Influenza Studies *Melicent Peck, Genentech, South San Francisco, California, USA* Baloxavir Marboxil, a Cap-Dependent Endonuclease Inhibitor - Development Updates *Takeki Uehara Shionogi & Co., Ltd, Osaka, Japan* RSV Antiviral Treatment for HCT patients: Results from Recent Phase 2 Studies for Presatovir *Michael Boeckh, Gilead, Foster City, CA, USA* Overview of RSV Programme *James Witek, Janssen Cilag, Titusville, New Jersey, USA* Nitazoxanide *John Beigel, NIAID, Bethesda, MD, USA*
10:35-11:00	**Coffee Break**

11:00-13:00	**Session 7:** Symposium- Clinical Trial and Regulatory Issues
	
	• FDA & EMA speakers- Topics to include:
	  ○ Trial designs for serious Influenza
	  ○ Therapeutic combinations (antivirals, adjunctive therapies)
	  ○ Statistical considerations/end points
	  ○ Pediatric considerations
	  ○ EMA perspective
	
	• Investigator perspective (influenza)
	Michael Ison, Northwestern University, Chicago, Illinois, USA
	
	• Discussion on RSV - FDA Guidance for Industry and Trial Designs/*Endpoint*
	FDA Speaker
	
	• Investigator perspective (RSV)
	John DeVincenzo, University of Tennessee, Memphis, Tennessee, USA

13:00-14:00	**Lunch**
14:00-15:00	**Session 8:** Roundtable Discussion- Clinical Trial and Regulatory Issues *Academic, Regulatory, and Industry representatives*
15:00-15:30	**Coffee Break**
15:30-17:00	**Session 9:** Oral Abstract Session 3- Clinical Papers (including disease pathogenesis, biomarkers, diagnostics)
17:00-18:00	Poster session 2

Thursday 15 November	
08:30-10:00	**Session 10:** Oral Abstract Session 4- Clinical Trial Papers
10:00-10:30	**Coffee Break**
10:30-12:30	**Session 11:** Hot Topics and Late-Breakers • Antiviral resistance monitoring strategies - *Aeron Hurt, WHO Collaborating Centre, Melbourne, Australia (TBC)* • Novel Coronaviruses - *Ralph Baric, University of North Carolina, Chapel Hill, NC, USA* • Adjunctive therapies - *Nelson Lee, University of Alberta, Edmonton, Canada*
12:30-13:00	Summary and close of conference
	Lunch and Depart